Bial, in excellence race with its ongoing clinical trial

Image Credit: Bial

Announcement 

Bial, a leading innovation-centric biopharmaceutical company targeting rare diseases and neurosciences, proudly mentioned its key progress in its current ACTIVATE (NCT05819359), phase 2 clinical trial examining the tolerability, efficacy, safety, pharmacokinetics and pharmacodynamics of BIA-28-6156 in patients suffering from parkinson’s disease (PD) which consist of pathogenic negligence in the glucocerebrosidase 1 (GBA1) gene (GBA-PD).

ACTIVATE study’s progress by far

The ACTIVATE study has, to date, enrolled 273 genetically confirmed GBA-PD patients across 85 sites in North America and Europe. Around 73 patients have completed their double-blind treatment duration of 78 weeks, and over 80% of engagers have come along with a one-year treatment journey effectively. These represent a key milestone in performing effective completion of the trial and entering into one of the finest clinical development eras of new treatment alternatives for parkinson’s disease, especially for GBA1 mutation patients. The last patient’s visit in this trial is planned in April 2026, with ranking results expected in the second quarter of 2026.

The BIA-28-6156 is in progress to become the best first-in-class small molecule for once daily oral administration to play the role of an allosteric activator of beta-glucocerebrosidase (Gcase), for the GBA-PD patient’s treatment. By accelerating the momentum of GCase, BIA 28-6156 can become the first ever drug to modify the main cause of the disease falling under this group of patients by redeveloping the sphingolipid recycling.

The head of clinical operations and study lead, Raquel Costa, said, “All the patients reached 52 weeks of the study is an unforgettable milestone. This has brought us near to getting the data required to thoroughly assess the efficacy and safety of BIA 28-6156, which can potentially become a required disease-modifying treatment for this patient group.”

The translating bial’s aim is on parkinson’s disease research and development, and the bial also confirmed its involvement in the coming International Congress of parkinson’s disease and movement disorders held on October 5-9 in Honolulu, USA. Bial will showcase a scientific poster differentiating a succession of non-motor symptoms in sporadic versus GBA-PD patients. The findings advise that above 6 6-year period, the symptoms are more extreme and progressive exponentially in GBA-PD patients in comparison to sporadic PD.

The poster presentation details include venue, time, date, presenter, and title, named ‘a 6-year longitudinal analysis from the parkinson’s Progression Markers Initiative on non-motor symptom severity and progression in GBA1-associated vs sporadic parkinson’s disease.’